Anti-Human CD178 (Fas-L) Biotin

Grouped product items
SizePrice Qty
25 ug
$90.00
100 ug
$220.00

Additional NOK-1 Formats

Cat.No.FormatStarting From
20811-80APC$ 110.00
20811-30Biotin$ 90.00
20811-20Purified$ 220.00
20811-25SAFIRE Purified$ 225.00
Catalog Number : 20811-30

description

The NOK-1 monoclonal antibody specifically reacts with human CD178, which is the CD95 or Fas ligand. CD178 is a TNF superfamily type II transmembrane glycoprotein expressed by activated T and NK cells and is involved in Fas-mediated apoptosis of lymphocytes. CD178 is also expressed by monocytes, neutrophils, granulocytes and the parenchymal cells of the retina and cornea. The NOK-1 antibody has been reported to bind to COOH-terminus of the Fas ligand in the region associated with Fas binding.

Additional Information

Clone:
NOK-1
Format:
Biotin
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest:Apoptosis, Cancer
Cell Type:T Cells, NK and NKT Cells
Application:FC
Clone:NOK-1
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., ... & Yagita, H. (1995). Metalloproteinase-mediated release of human Fas ligand.The Journal of experimental medicine182(6), 1777-1783.

Oyaizu, N., Adachi, Y., Hashimoto, F., McCloskey, T. W., Hosaka, N., Kayagaki, N., ... & Pahwa, S. (1997). Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. The Journal of Immunology158(5), 2456-2463.

Villunger, A., Egle, A., Marschitz, I., Kos, M., Böck, G., Ludwig, H., ... & Greil, R. (1997). Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood90(1), 12-20.

© BioGems International, Inc. All rights reserved.